Anderson, Mary Ann <br/><br/>
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.  [electronic resource] 

 -  Blood  06 2017 
 - 3362-3370 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2017-01-763003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Agammaglobulinaemia Tyrosine Kinase<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Bridged Bicyclo Compounds, Heterocyclic--therapeutic use<br/>Disease Progression<br/>Female<br/>Humans<br/>Karyotype<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Protein Kinase Inhibitors--therapeutic use<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-bcl-2--antagonists & inhibitors<br/>Retrospective Studies<br/>Sulfonamides--therapeutic use<br/>Treatment Outcome<br/>Vidarabine--analogs & derivatives<br/>Young Adult